INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025


PLYMOUTH MEETING, Pa., Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.

(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)

The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-second-quarter-2025-financial-results-on-august-12-2025-302520939.html

SOURCE INOVIO Pharmaceuticals, Inc.

Werbung

Inovio Pharmaceuticals Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Inovio Pharmaceuticals nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
15.02.18 Inovio Pharmaceuticals Buy Maxim Group
18.10.17 Inovio Pharmaceuticals Outperform RBC Capital Markets
24.05.17 Inovio Pharmaceuticals Buy Maxim Group
16.03.17 Inovio Pharmaceuticals Buy Maxim Group
07.11.16 Inovio Pharmaceuticals Buy Aegis Capital

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.